The safety of vedolizumab for the treatment of ulcerative colitis.
about
Infection risk with biologic therapy in patients with inflammatory bowel disease.Colitis Is Effectively Ameliorated by (±)-8-Acetonyl-dihydrocoptisine via the XBP1-NF-κB Pathway.Nodular Vasculitis in a Patient With Crohn's Disease on Vedolizumab.The Role of Integrin α4β7 in HIV Pathogenesis and Treatment.Safety and Positioning of Vedolizumab in Patients With Inflammatory Bowel Disease.
P2860
The safety of vedolizumab for the treatment of ulcerative colitis.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
The safety of vedolizumab for the treatment of ulcerative colitis.
@ast
The safety of vedolizumab for the treatment of ulcerative colitis.
@en
type
label
The safety of vedolizumab for the treatment of ulcerative colitis.
@ast
The safety of vedolizumab for the treatment of ulcerative colitis.
@en
prefLabel
The safety of vedolizumab for the treatment of ulcerative colitis.
@ast
The safety of vedolizumab for the treatment of ulcerative colitis.
@en
P2093
P2860
P1476
The safety of vedolizumab for the treatment of ulcerative colitis.
@en
P2093
Gregor Novak
Pieter Hindryckx
Reena Khanna
Vipul Jairath
P2860
P304
P356
10.1080/14740338.2017.1300251
P407
P577
2017-03-05T00:00:00Z